Tumor necrosis factor inhibitor therapy for rheumatoid arthritis

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


The immunopathology of rheumatoid arthritis (RA) is now better understood, and this knowledge has been translated into more effective therapy with biologic response modifiers. The first group of biologic response modifiers are the tumor necrosis factor inhibitors. There efficacy in controlling RA has been such that remission is now the goal of RA management. As with any patient treatment, safety is an issue; patients will need ongoing monitoring for infections, tumors, and other rare complications.

Original languageEnglish (US)
Pages (from-to)709-715
Number of pages7
JournalAnnals of the New York Academy of Sciences
StatePublished - 2005


  • Biologic response modifiers
  • Corticosteroids
  • Disease-modifying antirheumatic drugs
  • DMARDs
  • Rheumatoid arthritis
  • TNF-α inhibitors

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Tumor necrosis factor inhibitor therapy for rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this